Pfizer Inc. (NYSE:PFE) Stake Trimmed by Wellington Shields Capital Management LLC

Wellington Shields Capital Management LLC cut its position in shares of Pfizer Inc. (NYSE:PFE) by 1.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 30,313 shares of the biopharmaceutical company’s stock after selling 437 shares during the quarter. Wellington Shields Capital Management LLC’s holdings in Pfizer were worth $848,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of PFE. Gilbert & Cook Inc. grew its holdings in shares of Pfizer by 3.8% during the fourth quarter. Gilbert & Cook Inc. now owns 25,651 shares of the biopharmaceutical company’s stock valued at $738,000 after buying an additional 945 shares in the last quarter. Los Angeles Capital Management LLC grew its stake in Pfizer by 3.1% during the 4th quarter. Los Angeles Capital Management LLC now owns 29,864 shares of the biopharmaceutical company’s stock valued at $860,000 after acquiring an additional 899 shares in the last quarter. Gryphon Financial Partners LLC increased its holdings in shares of Pfizer by 43.7% in the 4th quarter. Gryphon Financial Partners LLC now owns 26,942 shares of the biopharmaceutical company’s stock valued at $861,000 after purchasing an additional 8,194 shares during the period. E Fund Management Co. Ltd. lifted its position in shares of Pfizer by 22.0% in the fourth quarter. E Fund Management Co. Ltd. now owns 13,922 shares of the biopharmaceutical company’s stock worth $401,000 after purchasing an additional 2,514 shares in the last quarter. Finally, Principal Securities Inc. acquired a new stake in shares of Pfizer during the fourth quarter worth approximately $2,393,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

NYSE PFE traded up $0.09 during trading on Friday, hitting $28.60. The company’s stock had a trading volume of 3,086,348 shares, compared to its average volume of 38,156,809. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $34.64. The firm has a market cap of $162.06 billion, a P/E ratio of -475.09, a price-to-earnings-growth ratio of 1.02 and a beta of 0.68. The firm has a 50 day moving average price of $29.05 and a 200 day moving average price of $28.04. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same period last year, the business posted $0.67 EPS. The business’s quarterly revenue was up 2.1% on a year-over-year basis. Equities research analysts forecast that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th were given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.87%. The ex-dividend date of this dividend was Friday, July 26th. Pfizer’s dividend payout ratio is presently -2,799.53%.

Analyst Ratings Changes

PFE has been the topic of several research reports. UBS Group upped their price objective on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Wells Fargo & Company upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Barclays lifted their price target on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and raised their target price for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Eight investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.